Vaxzevria – Oxford-AstraZeneca vaccine

If AstraZeneca (Vaxzevria) vaccination can potentially be linked to rare blood clotting events, is it better to wait to be vaccinated against COVID-19 until another vaccine is available?


It is safer to accept without delay any vaccine that is offered by national authorities to gain protection from COVID-19 as early as possible.

Before authorizing a vaccine for use in a country the national regulatory authority carefully assesses it for quality, efficacy and safety. AstraZeneca has been reviewed and authorized by WHO, the European Medicines Agency (EMA) and many countries around the world. WHO and EMA also recently reviewed the available safety data following 25 million doses administered in Europe and concluded again that the benefits of the vaccine outweigh any potential risks of side effects, and that the vaccine offers high protection against severe COVID-19 disease.

We need to remember that the risk of blood clotting events following COVID-19 infection is much higher than the risk of such events following vaccination.